Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces Proposed Public Offering of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 20, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has commenced an underwritten public offering of up to $150,000,000 of shares of
Toggle Summary Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
Landmark 554-patient Phase 3 study met the primary efficacy endpoint, as 67.2% of AR101 patients ages 4–17 tolerated at least a 600-mg dose of peanut protein in the exit food challenge, compared to 4.0% of placebo patients (p
Toggle Summary Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
— New Members Join International Board of Leading Academic Experts in Allergy and Immunology — — Prof. du Toit Is Lead Author of Landmark LEAP and LEAP-On Studies on Prevention of Peanut Allergy in Young Children — — Dr. Shreffler Is a Renowned Expert on Immunologic Mechanisms of Food Allergy —
Toggle Summary Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 12, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data during a late-breaking oral abstract session and in poster
Toggle Summary Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy
— Newly Expanded Global Agreement Secures Exclusive Supply Relationship through 2033 — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 10, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced an
Toggle Summary Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— PALISADE Completed in 2017; Topline Results Anticipated in February — — Late-Breaking Abstract Presentation at the 2018 American Academy of Allergy , Asthma & Immunology–World Allergy Organization Joint Congress in March — — PALISADE Follow-On Study, ARC004, Fully Enrolled — — RAMSES Real-World
Toggle Summary Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
— Presentation on Wednesday, January 10, 2018 , at 7:30 a.m. Pacific Time — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 3, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Stephen Dilly ,
Toggle Summary Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14
BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 7, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside chat at the BMO Capital
Toggle Summary Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017 .
Toggle Summary Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2017 .